WAYNE, Pa., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 42nd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis in San Francisco, California, on Tuesday, January 9, 2024, at 3:00 p.m. (PT).
A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor section of the Teleflex website at teleflex.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, QuikClot®, LMA®, Pilling®, Rüsch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.
Contacts:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
This email address is being protected from spambots. You need JavaScript enabled to view it.
610-948-2836
Last Trade: | US$178.16 |
Daily Change: | 3.37 1.93 |
Daily Volume: | 1,151,166 |
Market Cap: | US$8.270B |
November 07, 2024 October 29, 2024 October 23, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB